Envoy Medical Appoints Chas McKhann to Board of Directors
Newsfile (Thu, 16-Apr 8:00 AM ET)
Newsfile (Wed, 1-Apr 8:00 AM ET)
Envoy Medical Reports Full Year 2025 Financial Results
Newsfile (Mon, 23-Mar 8:30 AM ET)
Newsfile (Wed, 11-Mar 8:01 AM ET)
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
Newsfile (Tue, 24-Feb 8:01 AM ET)
Newsfile (Mon, 23-Feb 8:01 AM ET)
Newsfile (Thu, 19-Feb 8:01 AM ET)
Newsfile (Tue, 17-Feb 8:00 AM ET)
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering
Newsfile (Thu, 12-Feb 4:05 PM ET)
Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering
Newsfile (Wed, 11-Feb 9:25 AM ET)
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Envoy Medical - Class A trades on the NASDAQ stock market under the symbol COCH.
As of April 17, 2026, COCH stock price climbed to $0.71 with 196,307 million shares trading.
COCH has a beta of 1.00, meaning it tends to be more sensitive to market movements. COCH has a correlation of 0.02 to the broad based SPY ETF.
COCH has a market cap of $54.48 million. This is considered a Micro Cap stock.
Last quarter Envoy Medical - Class A reported $75,000 in Revenue and -$.26 earnings per share. This beat revenue expectation by $45,000 and missed earnings estimates by -$.02.
The top ETF exchange traded funds that COCH belongs to (by Net Assets): VXF, VTI, IWC.
COCH has underperformed the market in the last year with a price return of -47.1% while the SPY ETF gained +36.3%. However, in the short term, COCH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +3.1% vs +2.9% return in SPY. But in the last 2 weeks, COCH shares have been beat by the market, returning -5.2% compared to an SPY return of +8.3%.
COCH support price is $.65 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COCH shares will trade within this expected range on the day.
